Intellia Therapeutics (NTLA) Total Non-Current Liabilities (2015 - 2025)

Intellia Therapeutics (NTLA) has 9 years of Total Non-Current Liabilities data on file, last reported at $170.7 million in Q4 2025.

• Quarterly Total Non-Current Liabilities fell 46.49% year-over-year to $170.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $170.7 million (down 46.49% YoY) and the FY2025 annual result came in at $170.7 million, down 46.49% from the prior year.
• Total Non-Current Liabilities slipped to $170.7 million in Q4 2025 per NTLA's latest filing, from $319.1 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $319.1 million in Q4 2024 and bottomed at $170.7 million in Q4 2025.
• The 5-year median for Total Non-Current Liabilities is $238.1 million (2022), against an average of $236.8 million.
• The widest annual swing landed in 2024, when Total Non-Current Liabilities increased 27.21%; it then plunged 46.49% in 2025.
• Tracing NTLA's Total Non-Current Liabilities over 5 years: stood at $254.2 million in 2021, then rose by 2.47% to $260.5 million in 2022, then slipped by 3.72% to $250.8 million in 2023, then gained by 27.21% to $319.1 million in 2024, then sank by 46.49% to $170.7 million in 2025.
• Per Business Quant, the three latest NTLA Total Non-Current Liabilities figures stand at $170.7 million (Q4 2025), $319.1 million (Q4 2024), and $250.8 million (Q4 2023).

Peer Comparison